Randomized, double-blind, placebo-controlled study of carvedilol on the prevention of nitrate tolerance in patients with chronic heart failure

被引:27
|
作者
Watanabe, H
Kakihana, M
Ohtsuka, S
Sugishita, Y
机构
[1] KINU Med Assoc Hosp, Dept Cardiol, Mitsukaido City, Ibaraki 3030016, Japan
[2] Ibaraki Prefectural Univ Hlth Sci, Ami, Ibaraki, Japan
[3] Univ Tsukuba, Inst Clin Med, Dept Internal Med, Div Cardiovasc, Tsukuba, Ibaraki 305, Japan
关键词
D O I
10.1016/S0735-1097(98)00392-1
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives. This study was designed to evaluate the effect of carvedilol on nitrate tolerance in patients with chronic heart failure, Background. The attenuation of cyclic guanosine 5'-monophosphate (cGMP) production due to inactivation of guanylate cyclase by increased superoxide has been reported as a mechanism of nitrate tolerance. Carvedilol has been known to combine alpha/beta-blockade with antioxidant properties. Methods. To evaluate the effect of carvedilol on nitrate tolerance, 40 patients with chronic heart failure were randomized to four groups that received either carvedilol (2.5 mg once a day [carvedilol group, n = 10]), metoprolol (30 mg once a day [metoprolol group, n = 10]), doxazosin (0.5 mg once a day [doxazosin group, n = 10]) or placebo (placebo group, n = 10), Vasodilatory response to nitroglycerin (NTG) was assessed with forearm plethysmography by measuring the change in forearm blood flow (FBF) before and 5 min after sublingual administration of 0.3 mg NTG, and at the same time blood samples were taken from veins on the opposite side to measure platelet cGMP, Plethysmography and blood sampling were obtained serially at baseline (day 0); 3 days after carvedilol, metoprolol, doxazosin or placebo administration (day 3); and 3 days after application of a 10-mg/24-h NTG tape concomitantly with carvedilol, metoprolol, doxazosin or placebo (day 6), Results. There was no significant difference in the response of FBF (%FBF) and cGMP (%cGMP) to sublingual NTG on day 0 and day 3 among the four groups. On day 6, %FBF and %cGMP were significantly lower in the metoprolol, doxazosin and placebo groups than on day 0 and day 3, but these parameters in the carvedilol group were maintained. Conclusions. These results indicated that carvedilol may prevent nitrate tolerance in patients with chronic heart failure during continuous therapy,vith NTG. (C) 1998 by the American College of Cardiology.
引用
收藏
页码:1194 / 1200
页数:7
相关论文
共 50 条
  • [1] Randomized, double-blind, placebo-controlled comparative study between carvedilol and metoprolol in the prevention of nitrate tolerance in patients with chronic heart failure
    Watanabe, H
    Kakihana, M
    Ohtsuka, S
    Nakagawa, K
    Yamaguchi, I
    Sugishita, Y
    [J]. CIRCULATION, 1998, 98 (17) : 364 - 364
  • [2] Randomized, double-blind, placebo-controlled comparative study between carvedilol and arotinolol on the prevention of nitrate tolerance
    Watanabe, H
    Kakihana, M
    Ohtsuka, S
    Sugishita, Y
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1998, 31 (02) : 114A - 114A
  • [3] Randomized, double-blind, placebo-controlled study of ascorbate on the preventive effect of nitrate tolerance in patients with congestive heart failure
    Watanabe, H
    Kakihana, M
    Ohtsuka, S
    Sugishita, Y
    [J]. CIRCULATION, 1998, 97 (09) : 886 - 891
  • [4] Preventive effects of carvedilol on nitrate tolerance - A randomized, double-blind, placebo-controlled comparative study between carvedilol and arotinolol
    Watanabe, H
    Kakihana, M
    Ohtsuka, S
    Sugishita, Y
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1998, 32 (05) : 1201 - 1206
  • [5] Dietary nitrate supplementation and exercise tolerance in chronic heart failure: A double-blind, randomized, placebo-controlled, crossover trial
    Hirai, Daniel
    Zelt, Joel
    Jones, Joshua
    Bentley, Robert
    Earle, Wendy
    Staples, Patti
    Tschakovsky, Michael
    McCans, John
    O'Donnell, Denis
    Neder, J. Alberto
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2016, 48
  • [6] Randomized, double blind, placebo-controlled study of ascorbate on the preventive effect of nitrate tolerance in patients with congestive heart failure
    Watanabe, H
    Kakihana, M
    Ohtsuka, S
    Sugishita, Y
    [J]. CIRCULATION, 1997, 96 (08) : 175 - 175
  • [7] DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE LONG-TERM EFFICACY OF CARVEDILOL IN PATIENTS WITH SEVERE CHRONIC HEART-FAILURE
    KRUM, H
    SACKNERBERNSTEIN, JD
    GOLDSMITH, RL
    KUKIN, ML
    SCHWARTZ, B
    PENN, J
    MEDINA, N
    YUSHAK, M
    HORN, E
    KATZ, SD
    LEVIN, HR
    NEUBERG, GW
    DELONG, G
    PACKER, M
    [J]. CIRCULATION, 1995, 92 (06) : 1499 - 1506
  • [8] ENALAPRIL IN CHRONIC HEART-FAILURE, A DOUBLE-BLIND PLACEBO-CONTROLLED STUDY
    REMES, J
    NIKANDER, P
    REHNBERG, S
    HALINEN, MO
    KUIKKA, J
    LANSIMIES, E
    PYORALA, K
    [J]. ANNALS OF CLINICAL RESEARCH, 1986, 18 (03): : 124 - 128
  • [9] Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure - The PRECISE trial
    Packer, M
    Colucci, WS
    SacknerBernstein, JD
    Liang, CS
    Goldscher, DA
    Freeman, I
    Kukin, ML
    Kinhal, V
    Udelson, JE
    Klapholz, M
    Gottlieb, SS
    Pearle, D
    Cody, RJ
    Gregory, JJ
    Kantrowitz, NE
    LeJemtel, TH
    Young, ST
    Lukas, MA
    Shusterman, NH
    [J]. CIRCULATION, 1996, 94 (11) : 2793 - 2799
  • [10] Ursodeoxycholic Acid in Patients With Chronic Heart Failure A Double-Blind, Randomized, Placebo-Controlled, Crossover Trial
    von Haehling, Stephan
    Schefold, Joerg C.
    Jankowska, Ewa A.
    Springer, Jochen
    Vazir, Ali
    Kalra, Paul R.
    Sandek, Anja
    Fauler, Guenter
    Stojakovic, Tatjana
    Trauner, Michael
    Ponikowski, Piotr
    Volk, Hans-Dieter
    Doehner, Wolfram
    Coats, Andrew J. S.
    Poole-Wilson, Philip A.
    Anker, Stefan D.
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2012, 59 (06) : 585 - 592